| scholarly article | Q13442814 |
| P50 | author | Jessica E. Gosnell | Q110468263 |
| P2093 | author name string | Michael Skinner | |
| David Pfister | |||
| Annetta Krebs | |||
| James Vasselli | |||
| Martin Schlumberger | |||
| Robert F Gagel | |||
| Samuel A Wells | |||
| Julie A Sosa | |||
| Jeffrey Moley | |||
| P2860 | cites work | New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 |
| ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. | Q34166741 | ||
| Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. | Q34334980 | ||
| New therapeutic approaches to treat medullary thyroid carcinoma | Q34726233 | ||
| Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. | Q34989774 | ||
| Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features | Q35787996 | ||
| RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors | Q36200208 | ||
| Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer | Q36576959 | ||
| Toxicities of antiangiogenic therapy in non-small-cell lung cancer. | Q36713488 | ||
| Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension | Q36894975 | ||
| The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells | Q40105425 | ||
| ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. | Q44106085 | ||
| ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. | Q46469067 | ||
| Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors | Q46499714 | ||
| Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. | Q48114164 | ||
| Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases | Q51782295 | ||
| A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma | Q55670928 | ||
| A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors | Q80101020 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | thyroid cancer | Q826522 |
| patient | Q181600 | ||
| P304 | page(s) | 767-772 | |
| P577 | publication date | 2010-01-11 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer | |
| P478 | volume | 28 |
| Q35744505 | (111)In-octreotide scintigraphy for identification of metastatic medullary thyroid carcinoma in children and adolescents |
| Q36826533 | (3R,4S,5R)-Methyl 3,5-bis[(tert-butyldimethylsilyl)oxy]-4-methoxycyclohex-1-enecarboxylate |
| Q37290840 | 2012 European thyroid association guidelines for metastatic medullary thyroid cancer |
| Q31131055 | A Bayesian dose-finding design incorporating toxicity data from multiple treatment cycles |
| Q38139522 | A Drosophila approach to thyroid cancer therapeutics |
| Q43504942 | A Phase I Study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer |
| Q92381855 | A primer on the genetics of medullary thyroid cancer |
| Q86882953 | A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN) |
| Q92367546 | A rare cutaneous phototoxic rash after vandetanib therapy in a patient with thyroid cancer: A case report |
| Q36068707 | A systematic review and meta-analysis of the risk of diarrhea associated with vandetanib treatment in carcinoma patients |
| Q35206630 | Activated RET and ROS: two new driver mutations in lung adenocarcinoma |
| Q36857218 | Advanced medullary thyroid cancer: pathophysiology and management |
| Q37776660 | Advances in Cellular Therapy for the Treatment of Thyroid Cancer |
| Q89864998 | Advances in Targeting RET-Dependent Cancers |
| Q39364787 | Advances in small molecule therapy for treating metastatic thyroid cancer. |
| Q49988426 | Advances in the management of MEN2: from improved surgical and medical treatment to novel kinase inhibitors |
| Q38305056 | Advances in thyroid cancer treatment: latest evidence and clinical potential |
| Q89514362 | Angiocrine endothelium: from physiology to cancer |
| Q38389975 | Angiogenesis in cancer: Anti-VEGF escape mechanisms |
| Q37967243 | Angiogenesis: A Target in Solid Tumors, Also in Leukemia? |
| Q98158988 | Anlotinib as a molecular targeted therapy for tumors |
| Q37994504 | Anti-angiogenesis therapy in cancer: Current challenges and future perspectives |
| Q34695003 | Biomarkers for anti-angiogenic therapy in cancer. |
| Q38056076 | Cabozantinib for the Treatment of Advanced Medullary Thyroid Cancer |
| Q38625034 | Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer |
| Q38025824 | Cancer drugs and the heart: importance and management |
| Q38028798 | Cancer treatment according to BRCA1 and BRCA2 mutations |
| Q41251561 | Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma |
| Q54525027 | Chipping away at the lung cancer genome |
| Q37404382 | Clinical efficacy of targeted biologic agents as second-line therapy of advanced thyroid cancer |
| Q39593834 | Clinical trial design in head and neck cancer: what has the oncologist learned? |
| Q40309429 | Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer |
| Q44454430 | Clinically relevant genetic advances in endocrinology. |
| Q33803564 | Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics |
| Q35784523 | Combining the Multitargeted Tyrosine Kinase Inhibitor Vandetanib with the Antiestrogen Fulvestrant Enhances Its Antitumor Effect in Non-small Cell Lung Cancer |
| Q82918637 | Completing the Arc: Targeted Inhibition of RET in Medullary Thyroid Cancer |
| Q34906650 | Comprehensive assessment of the disputed RET Y791F variant shows no association with medullary thyroid carcinoma susceptibility |
| Q39345977 | Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines |
| Q51184181 | Current status of therapeutic approaches with targeted therapies in malignant thyroid cancer. Highlights from the 2011 ASCO Congress |
| Q37247181 | Current understanding and management of medullary thyroid cancer |
| Q26739366 | Cytotoxic and targeted therapy for hereditary cancers |
| Q35396089 | Diagnosis, treatment, and follow-up of medullary thyroid carcinoma: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism |
| Q38192670 | Do anti-angiogenic cancer therapies increase risk of significant weight loss? |
| Q33727633 | Doxorubicin combined with celecoxib inhibits tumor growth of medullary thyroid carcinoma in xenografted mice |
| Q37942884 | Drosophila as a tool for personalized medicine: a primer |
| Q35208929 | Drug therapy for hereditary cancers |
| Q36129640 | Dual Inhibition of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor is an Effective Chemopreventive Strategy in the Mouse 4-NQO Model of Oral Carcinogenesis |
| Q37387829 | Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid Cancer. |
| Q38058321 | Efficacy and tolerability of pharmacotherapy options for the treatment of medullary thyroid cancer |
| Q54978829 | Efficacy of Vandetanib in Treating Locally Advanced or Metastatic Medullary Thyroid Carcinoma According to RECIST Criteria: A Systematic Review and Meta-Analysis. |
| Q41837594 | Emerging role of multikinase inhibitors for refractory thyroid cancer |
| Q35370655 | Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches |
| Q37974717 | Emerging therapies for thyroid carcinoma |
| Q34574985 | Endocrine side effects of broad-acting kinase inhibitors |
| Q46784859 | Epidemiology of autosomal-dominant polycystic kidney disease: an in-depth clinical study for south-western Germany |
| Q64238257 | Evaluation of Polymer Nanoformulations in Hepatoma Therapy by Established Rodent Models |
| Q42914109 | Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study. |
| Q34608239 | Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders |
| Q46152995 | Exploiting Atropisomerism to Increase the Target Selectivity of Kinase Inhibitors |
| Q36983860 | FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review). |
| Q29249088 | Familial risk for lung cancer |
| Q37781666 | Familial thyroid neoplasia: impact of technological advances on detection and monitoring |
| Q86502052 | Four new drugs on the market: abiraterone, belatacept, vandetanib and fidaxomycine |
| Q90669004 | Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing |
| Q36184584 | Genetic and biochemical alterations in non-small cell lung cancer |
| Q54382047 | Good Clinical Response to Erlotinib in a Patient With Anaplastic Thyroid Carcinoma Harboring an Epidermal Growth Factor Somatic Mutation, L858R, in Exon 21 |
| Q56554243 | Guidelines for the management of thyroid cancer |
| Q42734821 | Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer |
| Q38263389 | Hereditary thyroid cancer syndromes and genetic testing |
| Q90178743 | Hospitalized cancer patients with acquired long QT syndrome-a matched case-control study |
| Q61804481 | Hypertension as a predictive biomarker in patients with advanced non-small-cell lung cancer treated with apatinib |
| Q35099457 | Hypoxia-inducible factor in thyroid carcinoma |
| Q35752400 | Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer |
| Q36941931 | Improvement of radioimmunotherapy using pretargeting |
| Q28480930 | Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis |
| Q36729895 | Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials |
| Q36024704 | Increased risk of severe infections in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis |
| Q39187613 | Influence of the multidrug transporter P-glycoprotein on the intracellular pharmacokinetics of vandetanib. |
| Q35977327 | Intracellular Signal Transduction and Modification of the Tumor Microenvironment Induced by RET/PTCs in Papillary Thyroid Carcinoma |
| Q35895485 | Kinase inhibitors for advanced medullary thyroid carcinoma |
| Q28072655 | Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer |
| Q42120502 | Linking model systems to cancer therapeutics: the case of Mastermind |
| Q38614511 | Long-Term Follow-up in Medullary Thyroid Carcinoma |
| Q38647947 | Management of advanced medullary thyroid cancer |
| Q37921599 | Management of medullary thyroid carcinoma and MEN2 syndromes in childhood. |
| Q83938036 | Management of refractory thyroid cancers |
| Q38268452 | Mechanisms that influence tumour response to VEGF-pathway inhibitors |
| Q27005897 | Medical management of metastatic medullary thyroid cancer |
| Q37983555 | Medullary Thyroid Cancer and Pseudocirrhosis: Case Report and Literature Review |
| Q38683133 | Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases |
| Q38046525 | Medullary Thyroid Cancer—Current Treatment Strategy, Novel Therapies and Perspectives for the Future |
| Q86433393 | Medullary Thyroid Carcinoma |
| Q35038893 | Medullary Thyroid Carcinoma: Molecular Signaling Pathways and Emerging Therapies |
| Q38931460 | Medullary Thyroid Carcinoma: Recent Advances Including MicroRNA Expression. |
| Q50918579 | Medullary thyroid carcinoma - Adverse events during systemic treatment: risk-benefit ratio |
| Q37673424 | Medullary thyroid carcinoma with ectopic adrenocorticotropic hormone syndrome |
| Q37822017 | Medullary, Anaplastic, and Metastatic Cancers of the Thyroid |
| Q47137441 | Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature |
| Q90194104 | Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice |
| Q26774734 | Molecular Targeted Therapies of Aggressive Thyroid Cancer |
| Q55564375 | Molecular Therapies in Thyroid Cancer. |
| Q38010030 | Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2 |
| Q89002621 | Multikinase Inhibitors for the Treatment of Progressive, Metastatic Medullary Thyroid Cancer - An Evolving Paradigm |
| Q26821959 | Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib |
| Q37921602 | Multikinase inhibitors: a new option for the treatment of thyroid cancer. |
| Q52985771 | Multimodal imaging with (18)F-FDG-PET/CT and (111)In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma |
| Q33587821 | Multiple Endocrine Neoplasia Type 2 and Familial Medullary Thyroid Carcinoma: An Update |
| Q28237010 | Multiple endocrine neoplasia type 2: an overview |
| Q35434188 | Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2. |
| Q58784257 | Navigating Systemic Therapy in Advanced Thyroid Carcinoma: From Standard of Care to Personalized Therapy and Beyond |
| Q39198933 | Nephrotoxicity of anticancer treatment |
| Q36361115 | New Treatment in Advanced Thyroid Cancer |
| Q35879431 | New agent to treat advanced or metastasized thyroid cancer, its efficacy, safety, and mechanism |
| Q26749308 | New drugs for medullary thyroid cancer: new promises? |
| Q40820078 | New targeted therapies for thyroid cancer |
| Q35381593 | New therapies for dedifferentiated papillary thyroid cancer |
| Q33864524 | New treatment modalities in advanced thyroid cancer |
| Q37872269 | Novel molecular targeted therapies for refractory thyroid cancer |
| Q38260495 | Novel therapies for thyroid cancer |
| Q64107734 | Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile |
| Q89703945 | Novel treatments for anaplastic thyroid carcinoma |
| Q37988794 | Occult primary medullary thyroid carcinoma presenting with pituitary and parotid metastases: case report and review of the literature. |
| Q47395532 | Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib |
| Q27005701 | Overview and management of dermatologic events associated with targeted therapies for medullary thyroid cancer |
| Q57590681 | PTENmutations: help spot thyroid cancer before it occurs |
| Q37974693 | Pazopanib for the treatment of breast cancer |
| Q57808230 | Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension |
| Q40922523 | Personalization of targeted therapy in advanced thyroid cancer |
| Q43237082 | Pharmacokinetic Drug Interactions with Vandetanib during Coadministration with Rifampicin or Itraconazole |
| Q38089099 | Pharmacokinetic evaluation of cabozantinib for the treatment of thyroid cancer |
| Q37970758 | Pharmacotherapy options for advanced thyroid cancer: a systematic review |
| Q36677934 | Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers |
| Q57295725 | Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer |
| Q54616228 | Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer |
| Q59376821 | Pretargeted radioimmunotherapy (pRAIT) in medullary thyroid cancer (MTC) |
| Q84294737 | Prognostic Impact of Serum Thyroglobulin Doubling-Time Under Thyrotropin Suppression in Patients with Papillary Thyroid Carcinoma Who Underwent Total Thyroidectomy |
| Q82182815 | Progress in Molecular Targeted Therapy for Thyroid Cancer: Vandetanib in Medullary Thyroid Cancer |
| Q37979656 | RET TKI: potential role in thyroid cancers. |
| Q30743260 | Realizing the promise of cancer predisposition genes |
| Q38365290 | Receptor tyrosine kinase inhibitors: Are they real tumor killers? |
| Q54550459 | Refractory thyroid cancers |
| Q34468665 | Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma |
| Q27026453 | Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis |
| Q35118673 | Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis |
| Q35884666 | Role of vandetanib in the management of medullary thyroid cancer |
| Q38546474 | Selective use of vandetanib in the treatment of thyroid cancer |
| Q37985518 | Signaling Pathways as Specific Pharmacologic Targets for Neuroendocrine Tumor Therapy: RET, PI3K, MEK, Growth Factors, and Notch |
| Q54397002 | Significances of RET fusion gene in non-small cell lung cancer |
| Q38118647 | Sorafenib and Thyroid Cancer |
| Q64889815 | Static Prognostic Factors and Appropriate Surgical Designs for Patients with Medullary Thyroid Carcinoma: The Second Report from a Single-Institution Study in Japan. |
| Q35748786 | Stevens-johnson syndrome induced by vandetanib |
| Q27678454 | Structural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase Domain |
| Q38966228 | Sunitinib for the treatment of thyroid cancer |
| Q38108096 | Surgical Approach to the Management of Medullary Thyroid Cancer: When Is Lymph Node Dissection Needed? |
| Q36788057 | Synergistic Action of a RAF Inhibitor and a Dual PI3K/mTOR Inhibitor in Thyroid Cancer |
| Q42966149 | Synthesis and in vivo evaluation of an (18)F-labeled glycoconjugate of PD156707 for imaging ETA receptor expression in thyroid carcinoma by positron emission tomography |
| Q36755366 | Systemic treatment for hereditary cancers: a 2012 update |
| Q37563869 | THE GORDON WILSON LECTURE EVOLUTION OF CLINICAL CANCER GENETICS. |
| Q38883187 | Targeted Therapies in Thyroid Cancer: An Extensive Review of the Literature |
| Q35147151 | Targeted Treatment of Differentiated and Medullary Thyroid Cancer |
| Q44262715 | Targeted agents for advanced thyroid cancer: "knowledge is power" - the role of multikinase inhibitors. |
| Q37825764 | Targeted therapies and thyroid cancer |
| Q37860132 | Targeted therapies for thyroid tumors. |
| Q84487202 | Targeted therapies: towards a new toxicology? |
| Q37875081 | Targeted therapy in refractory thyroid cancer: current achievements and limitations |
| Q38084056 | Targeted therapy in thyroid cancer |
| Q34810321 | Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model. |
| Q38107011 | Targeted therapy with kinase inhibitors in aggressive endocrine tumors |
| Q37798616 | Targeting RET Receptor Tyrosine Kinase Activation in Cancer |
| Q34739831 | Testicular and inguinal lymph node metastases of medullary thyroid cancer: a case report and review of the literature |
| Q88312410 | The Management of Medullary Thyroid Carcinoma in the Era of Targeted Therapy |
| Q38865611 | The Treatment of Advanced Thyroid Cancer in the Age of Novel Targeted Therapies |
| Q36526512 | The VEGF pathway in cancer and disease: responses, resistance, and the path forward. |
| Q53367275 | The development of rapid and accurate screening test for RET hotspot somatic and germline mutations in MEN2 syndromes |
| Q38168304 | The discovery and development of vandetanib for the treatment of thyroid cancer |
| Q36509363 | The genetic landscape of gastrointestinal stromal tumor lacking KIT and PDGFRA mutations |
| Q35744353 | The landscape and therapeutic relevance of cancer-associated transcript fusions. |
| Q50085302 | The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer |
| Q36508942 | The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. |
| Q38960074 | The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer. |
| Q38864998 | The safety of vandetanib for the treatment of thyroid cancer |
| Q37653174 | Therapeutic Additions and Possible Deletions in Oncology in 2011 |
| Q35092019 | Therapeutic melting pot of never in mitosis gene a related kinase 2 (Nek2): a perspective on Nek2 as an oncology target and recent advancements in Nek2 small molecule inhibition |
| Q57590701 | Thyroid cancer genetics: how close are we to personalizing clinical management? |
| Q37832117 | Thyroid cancer in 2010: a roadmap for targeted therapies |
| Q36328045 | Thyroid cancer: pathogenesis and targeted therapy |
| Q35509932 | Treating medullary thyroid cancer in the age of targeted therapy |
| Q38579925 | Treatment of advanced thyroid cancer: role of molecularly targeted therapies |
| Q35523958 | Tumor-suppressor role of Notch3 in medullary thyroid carcinoma revealed by genetic and pharmacological induction |
| Q37958678 | Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management |
| Q53109364 | Tyrosine kinase inhibitors for advanced or metastatic thyroid cancer: a meta-analysis of randomized controlled trials. |
| Q82918721 | Unusual Adverse Event With Vandetanib in Metastatic Medullary Thyroid Cancer |
| Q33570056 | Update: the status of clinical trials with kinase inhibitors in thyroid cancer |
| Q89632271 | Updates on the Management of Thyroid Cancer |
| Q38614514 | Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma |
| Q33885538 | Vandetanib |
| Q33984845 | Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer |
| Q42134527 | Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer |
| Q83523403 | Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR) |
| Q38064258 | Vandetanib and the management of advanced medullary thyroid cancer |
| Q26824828 | Vandetanib for the Treatment of Medullary Thyroid Cancer |
| Q38020834 | Vandetanib for the Treatment of Metastatic Medullary Thyroid Cancer |
| Q37967112 | Vandetanib for the Treatment of Thyroid Cancer |
| Q38164676 | Vandetanib for the treatment of medullary thyroid carcinoma |
| Q38185691 | Vandetanib for the treatment of thyroid cancer: an update |
| Q34757990 | Vandetanib in Children and Adolescents with Multiple Endocrine Neoplasia Type 2B Associated Medullary Thyroid Carcinoma |
| Q27692050 | Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies. |
| Q36910409 | Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial |
| Q35569079 | Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents |
| Q35576189 | Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial |
| Q38103781 | Vandetanib: A novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer |
| Q54573214 | Vandetanib: first global approval. |
| Q38020194 | Vandetanib: in medullary thyroid cancer |
| Q38098931 | Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma. |
| Q38250467 | Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations. |
| Q37840101 | XL184 (cabozantinib) for medullary thyroid carcinoma. |
Search more.